Evidence supporting the use of: Anti-aromatase
For the health condition: Fibroids (uterine)
Synopsis
Source of validity: Scientific
Rating (out of 5): 3
Aromatase inhibitors (anti-aromatase agents) have a scientific basis for use in the treatment of uterine fibroids (leiomyomas). Uterine fibroids are benign smooth muscle tumors whose growth is hormonally responsive, particularly to estrogen. Aromatase is the enzyme responsible for the conversion of androgens to estrogens, and increased local aromatase expression has been observed in fibroid tissue compared to normal myometrium. By inhibiting aromatase, these medications can reduce local and systemic estrogen levels, potentially suppressing fibroid growth. Clinical studies, though limited, have shown that aromatase inhibitors such as letrozole and anastrozole can reduce fibroid volume and alleviate symptoms like heavy menstrual bleeding. For instance, small randomized controlled trials and observational studies report a decrease in fibroid size and improvement in symptoms after several months of therapy. However, these studies often have small sample sizes and short durations, and aromatase inhibitors are not currently first-line therapy for fibroids. They are primarily considered in cases where other treatments (like GnRH agonists or surgery) are contraindicated or not effective. Overall, while the scientific rationale is sound and some clinical evidence supports their use, aromatase inhibitors are not yet standard therapy for fibroids. Larger, well-controlled studies are needed to better establish their efficacy and safety profile for this indication.
